Abstract
From 1990 to 1997, 16 consecutive patients with stage III and IVa invasive thymoma were treated in a single institution with primary chemotherapy consisting in adriamycin (40 mg m–2), cisplatin (50 mg m–2) administered intravenously on day 1, vincristine (0.6 mg m–2) on day 2 and cyclophosphamide (700 mg m–2) on day 4 (ADOC). The courses were repeated every 3 weeks. The aim was to evaluate the impact of this cytotoxic regimen with respect to response rate, per cent of patients radically resected, time to progression and overall survival. Two complete responses (one clinical and one pathological) and 11 partial responses were observed (overall response rate 81.2%); two patients had stable disease and one progressed. Toxicity was mild as only two patients developed grade III/IV neutropenia and one patient grade III nausea/vomiting. Nine patients were radically resected (five out of ten with stage III, and four out of six with stage IVa). Median time to progression and overall survival was 33.2 and 47.5 months respectively. Three patients were alive and disease free after more than 5 years. The ADOC scheme is highly active and manageable in the treatment of locally advanced thymoma. As a preoperative approach it should be offered to patients not amenable to surgery or to those surgically resectable but with a great deal of morbidity.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson, JR, Cain, KC & Gelber, RD (1983) Analysis of survival by tumor response. J Clin Oncol 1: 710–719.
Berruti, A, Borasio, P, Roncari, A, Gorzegno, G, Mossetti, C & Dogliotti, L (1993) Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 4: 429–431.
Curran, WJ, Kornstein, MJ, Brooks, JJ & Turrisi, T (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6: 1722–1727.
Decarli, A, La Vecchia, C, Cislaghi, C & Negri, E (1998) Cancer mortality in Italy, 1994, and an overview of trends from 1955 to 1994. Tumori 84: 312–334.
Fornasiero, A, Daniele, O, Ghiotto, C, Piazza, M, Fiore-Donati, L, Calabro’, F, Rea, F & Fiorentino, MV (1991) Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68: 30–33.
Giaccone, G, Musella, R, Bertetto, O, Donadio, M & Calciati, A (1985) Cisplatin-containing chemotherapy in the treatment of invasive thymoma: report of five cases. Cancer Treat Rep 69: 695–697.
Giaccone, G, Ardizzoni, A, Kirkpatrick, A, Clerico, M, Sahmoud, T & Van Zandwijk, N (1996) Cisplatin and etoposide combination for locally advanced or metastatic thymoma: a phase II study of the European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14: 814–820.
Kirschner, PA (1990) Reoperation for thymoma: report of 23 cases. Ann Thorac Surg 49: 550–555.
Kohman, JL (1997) Controversies in the management of malignant thymoma. Chest 112: 296S–300S.
Lewis, JE, Wick, MR, Scheithauer, BW, Bernatz, P & Taylor, WF (1987) Thymoma: a clinicopathologic review. Cancer 60: 2727–2743.
Loehrer, P, Kim, Km, Aisner, SC, Livingston, R, Einnhorn, LH, Johnson, D & Blum, R (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic recurrent thymoma: final results of an intergroup trial. J Clin Oncol 12: 1164–1168.
Loehrer, P, Chen, M, Kim, KM, Aisner, SC, Einnhorn, LH, Livingston, R & Johnson, D (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15: 3093–3099.
Macchiarini, P, Chella, A, Ducci, F, Rossi, B, Testi, C, Bevilacqua, G & Angeletti, A (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68: 706–713.
Maggi, G, Giaccone, G, Donadio, M, Ciuffreda, L, Dalesio, O, Leria, G, Trifiletti, G, Casadio, C, Palestro, G & Mancuso, M (1986) Thymomas: a review of 169 cases with particular reference to results of surgical treatment. Cancer 58: 765–776.
Maggi, G, Casadio, C, Cavallo, A, Cianci, R, Molinatti, M & Ruffini, E (1991) Thymoma: results of 241 operated cases. Ann Thorac Surg 51: 152–156.
Masaoka, A, Monden, Y, Nakahara, K & Tanioka, T (1981) Follow-up study of thymoma with reference to their clinical stages. Cancer 4: 2485–2492.
Miller, AB, Hoogstraten, B, Staquet, M & Winkler, A (1981) Reporting results of cancer treatment. Cancer 47: 207–214.
Nie, NH, Hull, CH & Jeakins, JG (1988). Statistical Package for the Social Sciences. SPSS Inc, Chicago IL
Pescarmona, E, Rendina, EA, Venuta, F, D’Arcangelo, E, Pagani, M, Ricci, C, Ruco, LP & Baroni, CD (1990) Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 50: 534–538.
Pollack, A, El-Naggar, AK, Cox, JD, RO, JY, Sahin, A & Komaki, R (1991) Thymoma: the prognostic significance of flow cytometric DNA analysis. Cancer 69: 1702–1709.
Rea, F, Sartori, F, Loy, M, Calabro’, F, Fornasiero, A, Daniele, O & Altavilla, G (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106: 543–549.
Schmidt, R, Monig, P, Selzner, M & Krug, B (1997) Surgical therapy of malignant thymoma. J Cardiovasc Surg 38: 317–322.
Shin, DM, Walsh, GL, Komaki, R, Putnam, JB, Nesbitt, J, Ro, JY, Shin, HJC, Ki, KH, Wimberly, A, Pisters, KMW, Schrump, D, Gregurich, MA, Cox, JD, Roth, JA & Hong, WK (1998) A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 129: 100–104.
Tomiak, EM & Evans, WK (1993) The role of chemotherapy in invasive thymoma: a review of the literature and considerations for future clinical trials. Crit Rev Oncol/Hematol 15: 113–242.
Urgesi, A, Monetti, U, Rossi, G, Ricardi, U, Maggi, G & Sannazzari, GL (1992) Aggressive treatment of intrathoracic recurrences of thymoma. Radiother Oncol 24: 221–225.
Verdecchia, A the Itacare working group (1997) Survival in adult Italian cancer patients. Tumori 83: 39–42.
Verley, JM & Hollmann, KH (1985) Thymoma: a comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer 55: 1074–1086.
Yagi, K, Hirata, T, Fukuse, T, Hiroyasu, Y, Kenji, I, Osamu, I, Hiroshi, M, Minoru, A, Shigeki, H & Hiromi, W (1996) Surgical treatment for invasive thymoma especially when the superior vena cava is invaded. Ann Thorac Surg 61: 521–524.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Berruti, A., Borasio, P., Gerbino, A. et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 81, 841–845 (1999). https://doi.org/10.1038/sj.bjc.6690773
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690773
Keywords
This article is cited by
-
Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy
Journal of Cancer Research and Clinical Oncology (2015)
-
Thymic malignancies focusing on systemic treatment
memo - Magazine of European Medical Oncology (2013)
-
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
British Journal of Cancer (2010)
-
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)
British Journal of Cancer (2009)
-
Chemotherapy in the treatment of thymic tumors
Oncology Reviews (2008)